Agile Therapeutics, Inc. (AGRX) CEO Alfred Altomari on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/12/20
Agile Therapeutics to Participate in Maxim Group’s Leading Innovators in Women’s Health Virtual ConferenceGlobeNewsWire • 08/11/20
Agile Therapeutics to Host Second Quarter 2020 Financial Results and Business Update Conference Call on Tuesday, August 11, 2020GlobeNewsWire • 07/21/20
How Agile Therapeutics (AGRX) Stock Stands Out in a Strong IndustryZacks Investment Research • 06/23/20
Agile Therapeutics, Inc. (AGRX) CEO Alfred Altomari on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/11/20
Is the Options Market Predicting a Spike in Agile Therapeutics (AGRX) Stock?Zacks Investment Research • 05/07/20
Agile Therapeutics (AGRX) Flat As Market Sinks: What You Should KnowZacks Investment Research • 04/01/20
Implied Volatility Surging for Agile Therapeutics (AGRX) Stock OptionsZacks Investment Research • 03/18/20
Is Agile Therapeutics (AGRX) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 02/21/20
Agile Therapeutics Announces Pricing of $45 Million Underwritten Public Offering of Common StockGlobeNewsWire • 02/21/20
Agile Therapeutics Announces Proposed Underwritten Public Offering of Common StockGlobeNewsWire • 02/20/20
Why This Analyst Sees New Contraceptive FDA Approval Doubling Agile Therapeutics Stock24/7 Wall Street • 02/18/20
FDA Approves Agile Therapeutics, Inc.’s Twirla® (levonorgestrel and ethinyl estradiol) Transdermal SystemGlobeNewsWire • 02/14/20